Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.36 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4469205 | 0.92 | CYP11B1 (0.44) | CYP11B1CYP11B2PPARGCCRL2ALDH1A1 | |
| SCHEMBL4466913 | 0.86 | CYP11B1 (0.44) | CYP11B1CYP11B2PPARGALDH1A1BRD4 | |
| SCHEMBL4467104 | 0.85 | FFAR4 (0.40) | CYP11B1CYP11B2LIPGLPL | |
| SCHEMBL27528495 | 0.84 | CYP11B1 (0.43) | CYP11B1CYP11B2PPARGALDH1A1BRD4 | |
| SCHEMBL27556671 | 0.82 | LIPG (0.37) | CYP11B1CYP11B2ALDH1A1CNR2CNR1 | |
| SCHEMBL6232997 | 0.82 | IDO1 (0.54) | ALDH1A1IDO1 | |
| SCHEMBL13708583 | 0.80 | SLC9A1 (0.35) | CYP11B1CYP11B2CNR2CNR1LIPG | |
| SCHEMBL4473805 | 0.78 | CYP11B1 (0.35) | CYP11B1CYP11B2ALDH1A1CNR2CRHR1 | |
| SCHEMBL4473718 | 0.78 | CYP11B1 (0.35) | CYP11B1CYP11B2ALDH1A1CNR2CRHR1 | |
| SCHEMBL4473169 | 0.78 | CYP11B1 (0.35) | CYP11B1CYP11B2ALDH1A1CNR2CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589117-B2 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-15 | — | — | US | disclosed |
| CN-1290833-C | N- ((3-oxo2, 3-dihydro-1H-isoindol-1-yl) acetyl) guanidine derivatives as NHE-1 inhibitors for the treatment of infarction and angina pectoris | SANOFI AVENTIS PHARMA GMBH (DE) | 2006-12-20 | — | — | CN | disclosed |
| US-7078428-B2 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-18 | — | — | US | disclosed |
| US-20060148880-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| EP-1528923-B1 | N-((3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-YL)ACETYL)GUANIDINE DERIVATIVES AS NHE1-INHIBITORS FOR THE TREATMENT OF INFARCTION AND ANGINA PECTORIS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-05-03 | — | — | EP | disclosed |
| CN-1658869-A | N- ((3-oxo-2, 3-dihydro-1H-isoindol-1-yl) acetyl) guanidine derivatives as NHE-1 inhibitors for the treatment of infarcts and angina pectoris | AVENTIS PHARMA GMBH (DE) | 2005-08-24 | — | — | CN | disclosed |
| EP-1528923-A1 | N-((3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-YL)ACETYL)GUANIDINE DERIVATIVES AS NHE1-INHIBITORS FOR THE TREATMENT OF INFARCTION AND ANGINA PECTORIS | Aventis Pharma Deutschland GmbH (DE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040048916-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUSCHLAND GMBH (DE) | 2004-03-11 | — | — | US | disclosed |
| WO-2003101450-A1 | N- ((3-OXO2, 3-DIHYDRO-1H-ISOINDOL-1-YL) ACETYL) GUANIDINE DERIVATIVES AS NHE-1 INHIBITORS FOR THE TREATMENT OF INFARCTION AND ANGINA PECTORIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148880-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | TNNI3, NDUFB3, NDUFB11 | CYP11B1 9/4885CYP11B2 13/4885PPARG 1645/4885 |
| US-20040048916-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | TNNI3, NDUFB3, NDUFB11 | CYP11B1 8/4885CYP11B2 18/4885PPARG 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.